The waiting has always been the problem—and now it might not be.
En el corazón de la medicina personalizada existe una paradoja cruel: la terapia más prometedora para ciertos cánceres agresivos requería tanto tiempo para fabricarse que algunos pacientes no llegaban a recibirla. Investigadores del Dana-Farber Cancer Institute en Boston han logrado comprimir el proceso de producción de células CAR-T para el mieloma múltiple —de varios meses a una mediana de 24 días— usando un producto celular llamado durcabtagene autoleucel en un ensayo de fase uno con 55 pacientes. Este avance no es solo técnico: es una respuesta directa al peso humano del tiempo cuando una enfermedad avanza más rápido que la ciencia podía seguirle el paso.
- Para pacientes con mieloma múltiple en progresión rápida, cada semana de espera representa una ventana que se cierra: el cáncer avanza mientras las células terapéuticas aún están en el laboratorio.
- Las terapias puente —quimioterapia u otros fármacos administrados durante la espera— son medidas de contención, no soluciones, y con frecuencia resultan insuficientes frente a una enfermedad que se duplica en semanas.
- El equipo del Dana-Farber, con apoyo de Novartis, demostró en un ensayo clínico de fase uno que es posible fabricar células CAR-T dirigidas contra BCMA en una mediana de 24 días, con un perfil de seguridad alentador en los 55 participantes.
- El tiempo récord de dos días logrado en laboratorio contrasta con los 24 días del entorno clínico real, que incluye selección de pacientes, extracción celular, fabricación, control de calidad e infusión.
- Si este protocolo acelerado se consolida como práctica estándar, podría transformar quién se beneficia de la terapia CAR-T y en qué momento de su enfermedad, inclinando la balanza hacia la remisión en lugar de la progresión.
En el Dana-Farber Cancer Institute de Boston, investigadores han abordado uno de los obstáculos más persistentes de la terapia CAR-T: el tiempo de fabricación. Para pacientes con mieloma múltiple cuya enfermedad avanza rápidamente, los meses que tardaba en producirse esta medicina viva podían resultar fatales. Ahora, trabajando con Novartis, el equipo ha demostrado que ese plazo puede reducirse a aproximadamente tres semanas.
Las células CAR-T son una forma de medicina personalizada: se extraen células inmunitarias del propio paciente, se reprograman en el laboratorio para atacar el cáncer y se reinfunden en el organismo. El proceso funciona, a veces de manera espectacular, pero la fabricación ha sido siempre un cuello de botella. Cuando el objetivo es BCMA —una proteína en la superficie de las células del mieloma—, la producción solía extenderse varios meses desde el inicio del tratamiento.
En un ensayo de fase uno con 55 pacientes con mieloma múltiple en recaída, el equipo utilizó un producto celular llamado durcabtagene autoleucel y logró una mediana de espera de solo 24 días, con un perfil de seguridad alentador. Los resultados fueron publicados en Science Translational Medicine.
Las implicaciones son concretas. Mientras esperan sus células, los pacientes reciben terapias puente —quimioterapia u otros fármacos— que solo contienen temporalmente la enfermedad. Acortar el proceso de fabricación significa que el paciente puede recibir su tratamiento cuando el cáncer aún es manejable, no tras meses de progresión adicional.
Los 24 días no son aún práctica habitual: reflejan lo alcanzado en un entorno de investigación con recursos dedicados y protocolos optimizados. Pero señalan lo que es posible. El mieloma múltiple es incurable con tratamientos convencionales, aunque las terapias más recientes han prolongado la supervivencia. El trabajo del Dana-Farber sugiere que la barrera de la fabricación —durante mucho tiempo un factor limitante— puede estar cediendo ante la ingeniería y la mejora de procesos, abriendo una ventana de esperanza para quienes más la necesitan.
At Dana-Farber Cancer Institute in Boston, researchers have cracked a problem that has haunted CAR-T cell therapy since its inception: the waiting. For patients with multiple myeloma whose cancer is advancing rapidly, the months required to manufacture personalized immune cells can mean the difference between remission and death. Now, a team working with Novartis has demonstrated that this timeline can be compressed to roughly three weeks.
CAR-T cells are a form of living medicine. Doctors extract a patient's own immune cells, reprogram them in the laboratory to recognize and attack cancer, then reinfuse them back into the bloodstream. The therapy works—sometimes dramatically. But the manufacturing process has always been a bottleneck. When targeting BCMA, a protein that sits on the surface of myeloma cells, production typically stretches across several months from the moment a patient enrolls in treatment. For someone whose cancer is doubling every few weeks, that delay can be fatal.
The researchers tested an accelerated manufacturing platform using a cell product called durcabtagene autoleucel. In a phase one trial involving 55 patients with relapsed multiple myeloma, they were able to produce the therapy for each participant with a median wait time of just 24 days. The results, published in Science Translational Medicine, showed that the cells maintained an encouraging safety profile—meaning patients tolerated the treatment without unexpected harm.
The human stakes here are concrete. Patients with rapidly progressing myeloma often face shorter survival windows and lower odds of treatment success. While they wait for their CAR-T cells to be manufactured, doctors can offer bridge therapies—chemotherapy or other drugs designed to hold the cancer in check temporarily. But these are holding actions, not solutions. The cancer often advances anyway. Shorten the manufacturing window, and you change the calculus entirely. A patient might receive their engineered cells while their disease is still manageable, rather than after months of additional progression.
The 24-day timeline is not yet routine. It represents what the team achieved in a controlled research setting with dedicated resources and optimized protocols. But it signals what is possible. The researchers had previously shown they could manufacture durcabtagene autoleucel in as little as two days in the laboratory. The 24-day figure reflects the full clinical pipeline—patient screening, cell collection, manufacturing, quality testing, and preparation for infusion. That is a meaningful compression of what has been standard practice.
Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. It is incurable with conventional treatment, though newer therapies have extended survival. CAR-T cell therapy represents one of the most promising recent advances, but only if patients can access it before their disease overwhelms them. The Dana-Farber work suggests that the manufacturing constraint—long a limiting factor in who could benefit and when—may finally be yielding to engineering and process improvement. For patients with aggressive forms of this disease, that acceleration could mean the difference between hope and time running out.
Citações Notáveis
Long manufacturing times can be unacceptable for patients with rapidly progressing myeloma, who often face shorter survival windows and lower treatment success rates— Dana-Farber researchers
A Conversa do Hearth Outra perspectiva sobre a história
Why does manufacturing take so long in the first place? It sounds like something you could speed up.
You're working with living cells, not chemicals. You extract a patient's immune cells, reprogram them genetically to recognize cancer, expand them to therapeutic numbers, test them for safety and function, and then prepare them for infusion. Each step has to work. You can't skip quality control on something going back into a person's bloodstream.
But they did it in two days in the lab. What's the gap between two days and 24 days?
The two-day figure is the pure manufacturing window under ideal conditions. The 24 days includes patient screening, cell collection from the patient, the manufacturing itself, regulatory testing, and preparation. It's the real-world timeline from when someone enrolls to when they get their cells back.
So the bottleneck isn't the science—it's the logistics and safety checks.
Exactly. And for someone whose cancer is doubling every few weeks, even 24 days can feel long. But it's a radical improvement over months. It means more patients might actually receive the therapy while they're still well enough to benefit from it.
What happens to the patients who can't wait? The ones whose cancer is too aggressive?
That's the human cost the trial is trying to address. They get bridge therapies—chemotherapy to try to slow things down—but those are temporary measures. By the time their CAR-T cells are ready, the disease has often progressed beyond the point where the therapy is effective. Cutting the wait time changes that equation.